Beranda › Sarkoma Ewing › Michigan
Uji klinis Sarkoma Ewing di Michigan
8 studi untuk Sarkoma Ewing mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- Helen DeVos Children's Hospital, Grand Rapids
Menerima pesertaFase 1
Usia 1 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07194044Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- University of Michigan, Ann Arbor
- START Midwest Michigan, PC, Grand Rapids
Menerima pesertaFase 1
Usia 12 hingga 85 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03715933Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Hospital of Michigan/Wayne State University, Detroit
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262Lurbinectedin in FET-Fused Tumors
- University of Michigan, Ann Arbor
Menerima pesertaFase 1/2
Usia 10 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- C S Mott Children's Hospital, Ann Arbor
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
- William Beaumont University Hospital, Royal Oak
Menerima peserta
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 6 Feb 2026 · NCT06387485Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Corewell Health, Grand Rapids
Menerima pesertaFase 1/2
Usia 2 hingga 30 · Semua jenis kelamin · Diperbarui 3 Feb 2026 · NCT05734066Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.